168 related articles for article (PubMed ID: 29560765)
1. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
Balian C; Garcia M; Ward J
J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
[TBL] [Abstract][Full Text] [Related]
2. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
4. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
[TBL] [Abstract][Full Text] [Related]
5. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
[TBL] [Abstract][Full Text] [Related]
6. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
[TBL] [Abstract][Full Text] [Related]
7. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Ali N; Adil SN; Shaikh MU
Transpl Infect Dis; 2014 Feb; 16(1):98-105. PubMed ID: 24383473
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection.
Zanwar S; Jain P; Gokarn A; Devadas SK; Punatar S; Khurana S; Bonda A; Pruthy R; Bhat V; Qureshi S; Khattry N
Transpl Infect Dis; 2019 Feb; 21(1):e13017. PubMed ID: 30369006
[TBL] [Abstract][Full Text] [Related]
10. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
Epstein L; See I; Edwards JR; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies.
El Boghdadly Z; Zhao Q; Koutou J; Lustberg ME; Ludwig M; Liscynesky C; Choe H
Leuk Lymphoma; 2022 Jun; 63(6):1455-1463. PubMed ID: 35001802
[TBL] [Abstract][Full Text] [Related]
12. Association between parenteral nutrition-containing intravenous lipid emulsion and bloodstream infections in patients with single-lumen central venous access: A secondary analysis of a randomized trial.
Gavin NC; Larsen E; Runnegar N; Mihala G; Keogh S; McMillan D; Ray-Barruel G; Rickard CM
JPEN J Parenter Enteral Nutr; 2023 Aug; 47(6):783-795. PubMed ID: 37288612
[TBL] [Abstract][Full Text] [Related]
13. Management of enterococcal central line-associated bloodstream infections in patients with cancer.
Awadh H; Chaftari AM; Khalil M; Fares J; Jiang Y; Deeba R; Ali S; Hachem R; Raad II
BMC Infect Dis; 2021 Jul; 21(1):643. PubMed ID: 34225651
[TBL] [Abstract][Full Text] [Related]
14. Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy.
de Mooij CEM; van der Velden WJFM; de Haan AFJ; Fazel S; van Groningen LFJ; Blijlevens NMA
Bone Marrow Transplant; 2022 Sep; 57(9):1373-1381. PubMed ID: 35661156
[TBL] [Abstract][Full Text] [Related]
15. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality.
Marena C; Zecca M; Carenini ML; Bruschi A; Bassi ML; Olivieri P; Azzaretti S; Locatelli F
Infect Control Hosp Epidemiol; 2001 Aug; 22(8):510-7. PubMed ID: 11700879
[TBL] [Abstract][Full Text] [Related]
16. Improving Oral Health and Modulating the Oral Microbiome to Reduce Bloodstream Infections from Oral Organisms in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation Recipients: A Randomized Controlled Trial.
Badia P; Andersen H; Haslam D; Nelson AS; Pate AR; Golkari S; Teusink-Cross A; Flesch L; Bedel A; Hickey V; Kramer K; Lane A; Davies SM; Thikkurissy S; Dandoy CE
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1704-1710. PubMed ID: 32505810
[TBL] [Abstract][Full Text] [Related]
17. Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: A single-center experience.
Chang AK; Foca MD; Jin Z; Vasudev R; Laird M; Schwartz S; Qureshi M; Kolb M; Levinson A; Bhatia M; Kung A; Garvin J; George D; Della-Latta P; Whittier S; Saiman L; Satwani P
Am J Infect Control; 2016 Dec; 44(12):1650-1655. PubMed ID: 27378008
[TBL] [Abstract][Full Text] [Related]
18. Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH;
Pediatr Blood Cancer; 2020 Aug; 67(8):e28234. PubMed ID: 32386095
[TBL] [Abstract][Full Text] [Related]
19. Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014.
See I; Soe MM; Epstein L; Edwards JR; Magill SS; Thompson ND
Am J Infect Control; 2017 Mar; 45(3):321-323. PubMed ID: 27856070
[TBL] [Abstract][Full Text] [Related]
20. Impact of infection control training for interns on PICU-acquired bloodstream infections in a middle-income country.
Ng YY; Abdel-Latif Mel-A; Gan CS; Siham A; Zainol H; Lum LC
Singapore Med J; 2015 Sep; 56(9):506-12. PubMed ID: 26451053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
